Clinical Trial

Magnesium Bisglycinate in Major Depressive Disorder

Study acronym: DReAM-BiG
Recruiting
View on ClinicalTrials.gov →
Summary
Depression is a common illness that can affect a person's mood, sleep, energy, ability to work, and overall quality of life. While medicines are available to treat depression, many people do not get complete relief from their symptoms. This study will evaluate whether adding a magnesium supplement in the form of magnesium bisglycinate to regular antidepressant treatment can help improve symptoms of depression. Adults with depression who are already receiving treatment will be randomly assigned to receive either magnesium bisglycinate or a placebo (an inactive substance) along with their usual medication. The study will compare the two groups to see whether the supplement leads to greater improvement in symptoms, sleep, and day-to-day functioning. Information on any side effects will also be collected. The findings may help determine whether magnesium bisglycinate can be used as a safe and affordable additional treatment for people with depression.
Protocol Amendment History 1 change
critical Recruitment opened 2026-06-16
Trial Details
NCT Number NCT07633080
Lead Sponsor All India Institute of Medical Sciences, Bhubaneswar
Conditions Major Depressive Disorder
Enrollment 84 participants
Start Date 2026-06-12
Primary Completion 2028-05-12 (estimated)
Study Completion 2028-06-12 (estimated)
Updated on ClinicalTrials.gov 2026-06-15